These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9271191)

  • 1. Preclinical AIDS vaccine development: formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates.
    Warren JT; Levinson MA
    J Med Primatol; 1997; 26(1-2):63-81. PubMed ID: 9271191
    [No Abstract]   [Full Text] [Related]  

  • 2. AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
    Warren JT; Levinson MA
    J Med Primatol; 1999; 28(4-5):249-73. PubMed ID: 10593492
    [No Abstract]   [Full Text] [Related]  

  • 3. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.
    Warren J
    J Med Primatol; 2002 Aug; 31(4-5):237-56. PubMed ID: 12390546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
    Warren JT; Dolatshahi M
    J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances in HIV vaccine preclinical studies using Macaque models.
    Liang B; Li H; Li L; Omange RW; Hai Y; Luo M
    Vaccine; 2019 Jun; 37(26):3388-3399. PubMed ID: 31088747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.
    Staprans SI; Feinberg MB
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S5-32. PubMed ID: 15285703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
    Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of nonpathogenic nef-deleted SHIV vaccination combined with recombinant IFN-gamma administration against a pathogenic SHIV challenge in rhesus monkeys.
    Kaneyasu K; Kita M; Ohkura S; Yamamoto T; Ibuki K; Enose Y; Sato A; Kodama M; Miura T; Hayami M
    Microbiol Immunol; 2005; 49(12):1083-94. PubMed ID: 16365534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.
    Stott EJ; Almond N; Kent K; Walker B; Hull R; Rose J; Silvera P; Sangster R; Corcoran T; Lines J; Silvera K; Luciw P; Murphy-Corb M; Momin P; Bruck C
    J Gen Virol; 1998 Mar; 79 ( Pt 3)():423-32. PubMed ID: 9519819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies and resistance to natural HIV infection.
    Nabel GJ; Sullivan NJ
    N Engl J Med; 2000 Oct; 343(17):1263-5. PubMed ID: 11071680
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
    Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
    Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine.
    Igarashi T; Ami Y; Yamamoto H; Shibata R; Kuwata T; Mukai R; Shinohara K; Komatsu T; Adachi A; Hayami M
    J Gen Virol; 1997 May; 78 ( Pt 5)():985-9. PubMed ID: 9152414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.